Vaccines for the elderly

Gerontology

Volumn 61, Issue 3, 2015, Pages 203-210

  Del Giudice, Giuseppe ^a   Weinberger, Birgit ^b   Grubeck Loebenstein, Beatrix ^a  

^a NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

^b UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

Elderly; Immune system; Immunosenescence; Vaccine technology

Indexed keywords

AVIAN INFLUENZA VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; INFLUENZA VACCINE; LIVE VACCINE; PNEUMOCOCCUS VACCINE; POLYSACCHARIDE VACCINE; RAPAMYCIN; RESPIRATORY SYNCYTIAL VIRUS VACCINE; SUBUNIT VACCINE; VACCINE; VARICELLA ZOSTER VACCINE;

ADAPTIVE IMMUNITY; AGED; AGING; CYTOMEGALOVIRUS INFECTION; DIPHTHERIA; DRUG DESIGN; DRUG EFFICACY; DRUG MANUFACTURE; GROUPS BY AGE; HERPES ZOSTER; HOLISTIC CARE; HOSPITALIZATION; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNIZATION; IMMUNOGENICITY; INFECTION; INFECTION PREVENTION; INFLUENZA; NONHUMAN; PERTUSSIS; PNEUMOCOCCAL INFECTION; PRIMARY IMMUNE RESPONSE; PRIORITY JOURNAL; REVIEW; TETANUS; VIRUS NEUTRALIZATION; FEMALE; GERIATRICS; IMMUNOCOMPETENCE; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; INFLUENZA, HUMAN; MALE; PROCEDURES; VACCINATION; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AGING; FEMALE; GERIATRICS; HUMANS; IMMUNE TOLERANCE; IMMUNOCOMPETENCE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; VACCINATION; VACCINES;

EID: 84929029414     PISSN: 0304324X     EISSN: 14230003     Source Type: Journal    
DOI: 10.1159/000366162     Document Type: Review

References (56)

1. United Nations: Profiles of Ageing. 2013. United Nations, Department of Economic and Social Affairs, Population Division. http://www. un.org/en/development/desa/population/ publications/dataset/urban/profilesOf Ageing2013.shtml (accessed May 10, 2014).
2. Gavazzi G, Krause KH: Ageing and infection. Lancet Infect Dis 2002; 2: 659-666.
3. Boraschi D, Aguado MT, Dutel C, Goronzy J, Louis J, Grubeck-Loebenstein B, Rappuoli Ri, Del Giudice G: The gracefully aging immune system. Science Transl Med 2013; 5: 185ps8.
4. Pang WW, Price EA, Sahoo D, Beerman I, Maloney WJ, Rossi DJ, Schrier SL, Weissman IL: Human bone marrow hematopoietic stem cells are increased in frequency and myeloidbiased with age. Proc Natl Acad Sci U S A 2011; 108: 20012-20017.
5. Gayoso I, Sanchez-Correa B, Campos C, Alonso C, Pera A, Casado JG, Morgado S, Parazona R, Solana R: Immunosenescence of human natural killer cells. J Innate Immun 2011; 3: 337-343.
6. Shaw AC, Goldstein DR, Montgomery RR: Age-dependent dysregulation of innate immunity. Nat Rev Immunol 2013; 13: 875-887.
7. Franceschi C, Bonafe M, Valensin S, Olivieri F, De Luca M, Ottaviani E, De Benedictis G: Inflamm-aging. An evolutionary perspective on immunosenescence. Ann NY Acad Sci 2000; 908: 244-254.
8. Shaw AC, Panda A, Joshi SR, Qian F, Allore HG, Montgomery RR: Dysregulation of human toll-like receptor function in aging. Ageing Res Rev 2011; 10: 346-353.
9. Ireton GC, Reed SG: Adjuvants containing natural and synthetic toll-like receptor 4 ligands. Expert Rev Vaccines 2013; 12: 793-807.
10. Arnold CR, Wolf J, Brunner S, Herndler-Brandstetter D, Grubeck-Loebenstein B: Gain and loss of T cell subsets in old age-age-related reshaping of the T cell repertoire. J Clin Immunol 2011; 31: 137-146.
11. Almanzar G, Schwaiger S, Jenewein B, Keller M, Herndler-Brandstetter D, Wurzner R, Schonitzer D, Grubeck-Loebenstein B: Longterm cytomegalovirus infection leads to significant changes in the composition of the CD8+ T-cell repertoire, which may be the basis for an imbalance in the cytokine production profile in elderly persons. J Virol 2005; 79: 3675-3683.
12. Cambier J: Immunosenescence: A problem of lymphopoiesis, homeostasis, microenvironment, and signaling. Immunol Rev 2005; 205: 5-6.
13. Scholz JL, Diaz A, Riley RL, Cancro MP, Frasca D: A comparative review of aging and B cell function in mice and humans. Curr Opin Immunol 2013; 25: 504-510.
14. Frasca D, Blomberg BB: Effects of aging on B cell function. Curr Opin Immunol 2009; 21: 425-430.
15. Gibson KL, Wu YC, Barnett Y, Duggan O, Vaughan R, Kondeatis E, Nilsson BO, Wikby A, Kipling D, Dunn-Walters DK: B-cell diversity decreases in old age and is correlated with poor health status. Aging Cell 2009; 8: 18-25.
16. Thompson WW, Shay DK, Weintraub E, Brammer L, Cox NJ, Anderson LJ, Fukuda K: Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003; 289: 179-186.
17. Thompson WW, Shay DK, Weintraub E, Brammer L, Bridges CB, Cox NJ, Fukuda K: Influenza-associated hospitalizations in the United States. JAMA 2004; 292: 1333-1340.
18. Falsey AR: Respiratory syncytial virus in adults. Semin Respir Crit Care Med 2007; 28: 171-181.
19. Schmader K: Herpes zoster in older adults. Clin Infect Dis 2001; 32: 1481-1486.
20. Janssens JP, Krause KH: Pneumonia in the very old. Lancet Infect Dis 2004; 4: 112-124.
21. Edwards MS, Baker CJ: Group B streptococcal infection in elderly adults. Clin Infect Dis 2005; 41: 839-847.
22. Blank PR, Schwenkglenks M, Szucs TD: Influenza vaccination coverage rates in five European countries during season 2006/07 and trends over six consecutive years. BMC Public Health 2008; 8: 272
23. Goodwin K, Viboud C, Simonsen L: Antibody response to influenza vaccination in the elderly: A quantitative review. Vaccine 2006; 24: 1159-1169.
24. Melegaro A, Edmunds WJ: The 23-valent pneumococcal polysaccharide vaccine. Part I. Efficacy of PPV in the elderly: A comparison of meta-analyses. Eur J Epidemiol 2004; 19: 353-363.
25. de Roux A, Schmöle-Thoma B, Siber GR, Hackell JG, Kuhnke A, Ahlers N, Baker SA, Razmpour A, Emini EA, Fernsten PD, Gruber WC, Lockhart S, Burkhardt O, Welte T, Lode HM: Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: conjugate vaccine elicits improved antibacterial immune responses and immunological memory. Clin Infect Dis 2008; 46: 1015-1023.
26. Pfizer: Press release. 2014. http://www.pfizer. com/news/press-release/press-release-detail/ pfizer-announces-positive-top-line- results-of-landmark-community-acquired- pneumonia-immunization-trial-in-adults- capita-evaluating-efficacy-of-prevenar-13 (accessed May 10, 2014).
27. Levin MJ: Immune senescence and vaccines to prevent herpes zoster in older persons. Curr Opin Immunol 2012; 24: 494-500.
28. Weinberger B, Grubeck-Loebenstein B: Vaccines for the elderly. Clin Microbiol Infect 2012; 18(suppl 5):100-108.
29. Ridda I, Yin JK, King C, MacIntyre CR, Mc-Intyre P: The importance of pertussis in older adults: A growing case for reviewing vaccination strategy in the elderly. Vaccine 2012; 30: 6745-6752.
30. Greenberg DP: Fluzone ® high-dose vaccine. FIM12 efficacy trial. Presentation at ACIP Meeting, October 24, 2013. http://www.cdc. gov/vaccines/acip/meetings/downloads/ slides-oct-2013/04-Fluzone-Greenberg.pdf (accessed May 10, 2014).
31. Leroux-Roels I, Leroux-Roels G, Clement F, Vandepapelière P, Vassilev V, Ledent E, Heineman TC: A phase 1/2 clinical trial evaluating safety and immunogenicity of a varicella zoster glycoprotein E subunit vaccine candidate in young and older adults. J Infect Dis 2012; 206: 1280-1290.
32. Halperin W, Weiss WI, Altman R, Diamond MA, Black KJ, Iaci AW, Black HC, Goldfield M: A comparison of the intradermal and subcutaneous routes of influenza vaccination with A/New Jersey/76 (swine flu) and A/Victoria/ 75: report of a study and review of the literature. Am J Public Health 1979; 69: 1247-1250.
33. Holland D, Booy R, De Looze F, Eizenberg P, McDonald J, Karrasch J, McKeirnan M, Salem H, Mills G, Reid J, Weber F, Saville M: Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: A randomized controlled trial. J Infect Dis 2008; 198: 650-658.
34. Gelink LBS, van den Bemt BJF, van der Bijl AE, Visser LG, Cats HA, Rimmelzwaan GF, Kroon FP: Intradermal influenza vaccination in immunocompromized patients is immunogenic and feasible. Vaccine 2009; 27: 2469-2474.
35. O'Hagan DT, Ott GS, Nest GV, Rappuoli R, Del Giudice G: The history of MF59 ® adjuvant: A phoenix that arose from the ashes. Expert Rev Vaccines 2013; 12: 13-30.
36. Del Giudice G, Fragapane E, Della Cioppa G, Rappuoli R: Aflunov ® : A vaccine tailored for pre-pandemic and pandemic approaches against influenza. Expert Opin Biol Ther 2013; 13: 121-135.
37. Khurana S, Chearwae W, Castellino F, Manischewitz J, King LR, Honorkiewicz A, Rock MT, Edwards KM, Del Giudice G, Rappuoli R, Golding H: Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus. Sci Transl Med 2010; 2: 15ra5.
38. Khurana S, Verma N, Yewdell JW, Hilbert AK, Castellino F, Lattanzi M, Del Giudice G, Rappuoli R, Golding H: MF59 adjuvant enhances diversity and affinity of antibodymediated immune response to pandemic influenza vaccines. Sci Transl Med 2011; 3: 85ra48.
39. Vesikari T, Knuf M, Wutzler P, Karvonen A, Kieninger-Baum D, Schmitt HJ, Baehner F, Borkowski A, Tsai TF, Clemens R: Oil-in-water emulsion adjuvant with influenza vaccine in young children. N Engl J Med 2011; 365: 1406-1416.
40. Mannino S, Villa M, Apolone G, Weiss NS, Groth N, Aquino I, Boldori L, Caramaschi F, Gattinoni A, Malchiodi G, Rothman KJ: Effectiveness of adjuvanted influenza vaccination in elderly subjects in northern Italy. Am J Epidemiol 2012; 176: 527-533.
41. Van Buynder PG, Konrad S, Van Buynder JL, Brodkin E, Krajden M, Ramler G, Bigham M: The comparative effectiveness of adjuvanted and unadjuvanted trivalent inactivated influenza vaccine (TIV) in the elderly. Vaccine 2013; 31: 6122-6128.
42. Calabro S, Tritto E, Pezzotti A, Taccone M, Muzzi A, Bertholet S, De Gregorio E, O'Hagan DT, Baudner B, Seubert A: The adjuvant effect of MF59 is due to the oil-in-water emulsion formulation, none of the individual components induce a comparable adjuvant effect. Vaccine 2013; 31: 3363-3369.
43. Garçon N, Vaughn DW, Didierlaurent AM: Development and evaluation of AS03, an adjuvant system containing tocopherol and squalene in an oil-in-water emulsion. Expert Rev Vaccines 2012; 11: 349-366.
44. McElhaney JE, Beran J, Devaster JM, et al; Influence65 study group: AS03-adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: A phase 3 randomised trial. Lancet Infect Dis 2013; 13: 485-496.
45. Even-Or O, Samira S, Ellis R, Kedar E, Barenholz Y: Adjuvanted influenza vaccines. Expert Rev Vaccines 2013; 12: 1095-1108.
46. Gil A, Oyaguez I, Carrasco P, Gonzalez A: Hospital admissions for pertussis in Spain, 1995-1998. Vaccine 2011; 19: 4791-4794.
47. Halperin SA, Scheifele D, De Serres G, Noya F, Meekison W, Zickler P, Larrivée L, Langley JM, McNeil SA, Dobson S, Jordanov E, Thakur M, Decker MD, Johnson DR: Immune responses in adults to revaccination with a tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine 10 years after a previous dose. Vaccine 2012; 30: 974-982.
48. Shaw CA, Ciarlet M, Cooper BW, Dionigi L, Keith P, O'Brien KB, Rafie-Kolpin M, Dormitzer PR: The path to an RSV vaccine. Curr Opin Virol 2013; 3: 332-342.
49. Kaslow DC, Shiver JW: Clostridium difficile and methicillin-resistant Staphylococcus aureus : emerging concepts in vaccine development. Annu Rev Med 2011; 62: 201-215.
50. Karas JA, Enoch DA, Aliyu SH: A review of mortality due to Clostridium difficile infection. J Infect 2010; 61: 1-8.
51. Reichert TA, Sugaya N, Fedson DS, Glezen WP, Simonsen L, Tashiro M: The Japanese experience with vaccinating schoolchildren against influenza. N Engl J Med 2001; 344: 889-896.
52. Sansoni P, Vescovini R, Fagnoni FF, et al: New advances in CMV and immunosenescence. Exp Gerontol 2014; 55C:54-62.
53. Pass RF, Zhang C, Evans A, Simpson T, Andrews W, Huang ML, Corey L, Hill J, Davis E, Flanigan C, Cloud G: Vaccine prevention of maternal cytomegalovirus infection. N Engl J Med 2009; 360: 1191-1199.
54. Lamming DW, Ye L, Sabatini DM, Baur JA: Rapalogs and mTOR inhibitors as anti-aging therapeutics. J Clin Invest 2013; 123: 980-989.
55. Keating R, Hertz T, Wehenkel M, Harris TL, Edwards BA, McClaren JL, Brown SA, Surman S, Wilson ZS, Bradley P, Hurwitz J, Chi H, Doherty PC, Thomas PG, McGargill MA: The kinase mTOR modulates the antibody response to provide cross-protective immunity to lethal infection with influenza virus. Nat Immunol 2013; 14: 1266-1176.
56. Lucas CL, Kuehn HS, Zhao F, et al: Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110 result in T cell senescence and human immunodeficiency. Nat Immunol 2014; 15: 88-97.